Based on an improved understanding of the epigenetic landscape of NSCLC, clinical applications for targeting epigenetics in its treatment became viable with a variety of epigenetic regulators, such as DNMT, HDAC, and HDAC6 [25]. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.